TPC‐EV treatment increased both CD31 and α‐SMA densities in tumour tissues when compared to the vehicle groups; however, the differences of α‐SMA densities in TPC‐EV‐(siNC)‐ and TPC‐EV‐(siGas6)‐treated groups were not statistically significant, which indicated that there might be several EV proteins in TPC‐EV‐(siGas6) that could regulate the proliferation and/or recruitment of α‐SMA‐positive cells. Here, PECAM1 is linked to neoplasm.